Revolution Medicines, Inc. RVMD
Free cash flow down to -$913.7M
XBRL, from each 10-KThe latest figures
Price and key numbers
All key numbers (30, from the latest 10-K and 10-Q)
- EPS (ttm)
- -9.13
- Sales (ttm)
- 197.6M
- Net income (ttm)
- -1.9B
- Sales growth
- -
- EPS growth
- -
- Sales Q/Q
- -
- Free cash flow
- -1.4B
- Gross margin
- -
- Oper. margin
- -853.0%
- Net margin
- -946.8%
- FCF margin
- -729.3%
- ROE
- -77.9%
- ROA
- -43.5%
- R&D / sales
- -
- Dividend
- -
- Debt/Eq
- -
- Curr. ratio
- 8.36
- Cash
- 615.9M
- Op. cash flow (ttm)
- -1.4B
- EBITDA
- -1.2B
- Quick ratio
- 8.36
- Interest cover
- -48.80
- FCF after stock pay
- -1.0B
- Goodwill / assets
- 0.6%
- Shares out.
- 216.3M
- Shares Y/Y
- +13.3%
- Book / share
- 11.10
- Cash / share
- 2.85
- Sales / share
- 0.91
- Asset turnover
- 0.05
Hover or tap a number to see the XBRL line item and filing it comes from; click it to open that filing at SEC. What each number means. Looks wrong? Tell us.
Revenue and net income, FY2018 to FY2025
Each fiscal year from its own 10-K · XBRL
From XBRL in each 10-K. Hover a bar for the line item and filing.
What the balance sheet holds, per share
Net current asset value and tangible book value, FY2025 · 10-K XBRL, no share price used
- + Shareholders' equity $1.6B
- − Goodwill $14.6M
- − Other intangible assets $55.8M
- = Tangible book value $1.6B
Net current asset value is current assets minus all liabilities (the long-term ones too), so it is what would be left from the short-term assets after everything owed is paid; it is blank for a bank, which reports no current assets. Tangible book value is shareholders' equity minus goodwill and other intangible assets; equity includes any preferred stock. Both are divided by the diluted weighted-average share count of the same fiscal year. Red bars are amounts taken off, or a negative result.
RVMD against Health care peers
Among the 162 companies, the better end on the right. The band holds the middle half; the line is the median.
| Company | Revenue (ttm) | Sales growthFY | Gross marginttm | Net marginttm | ROEttm | FCF marginttm | Debt / equitylatest |
|---|---|---|---|---|---|---|---|
| RVMD Revolution Medicines, Inc. | $197.6M | - | - | -946.8% | -77.9% | -729.3% | - |
| LMAT Lemaitre Vascular Inc | $269.4M | +13.5% | 72.0% | 23.5% | 14.7% | 24.9% | - |
| LGND Ligand Pharmaceuticals Inc | $253.8M | +60.4% | - | 20.3% | 5.4% | 35.7% | 1.17 |
| GRAL GRAIL, Inc. | $166.6M | +17.2% | - | -243.8% | -16.6% | -187.3% | - |
| BEAM Beam Therapeutics Inc. | $146.6M | +120% | - | -73.9% | -11.4% | -271.6% | 0.11 |
| AGIO Agios Pharmaceuticals, Inc. | $140.8M | +48.0% | 93.8% | -264.8% | -38.1% | -238.5% | - |
Profitability
-
Net margin below the peer median-946.8% vs 6.8%
-
Return on equity below 15%-77.9%
-
A profit in 0 of 8 years
Balance sheet
-
Interest covered less than 5 timesOperating income is -48.8× interest expense
-
Current assets cover current liabilitiesCurrent ratio 8.36
Cash and shareholders
-
Free cash flow positive in 0 of 8 years−$913.7M last year
-
Share count up over 5 years+131.0%
Each tick is a fact with a fixed rule (on /methodology), not a score or advice. A check without the numbers it needs is left out.
Income statement, balance sheet and cash flow
Statements · XBRL, each 10-K and 10-Q
RVMD's income statement, balance sheet and cash flow as reported to the SEC in XBRL, one column per fiscal year, the last 8. Hover a number to see the line item and filing it comes from. Where a company changed how it tags a line, the first tag it reported for that period is used. A number looks wrong? Tell us.
Income statement
From EDGAR| FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 20.2M | 50.0M | 43.0M | 29.4M | 35.4M | 11.6M | 0 | 0 |
| R&D | 51.1M | 91.8M | 132.3M | 186.9M | 253.1M | 423.1M | 592.2M | 987.3M |
| SG&A | 9.4M | 12.4M | 21.4M | 30.4M | 40.6M | 75.6M | 97.3M | 195.0M |
| Operating income | -40.3M | -54.1M | -110.7M | -188.0M | -258.3M | -487.2M | -689.5M | -1.2B |
| Interest expense | 116K | 106K | 71K | 12K | 0 | 0 | 0 | 24.2M |
| Pretax income | -41.8M | -52.0M | -108.5M | -187.1M | -249.1M | -439.9M | -600.8M | -1.1B |
| Income tax | - | -4.4M | -371K | 0 | -420K | -3.5M | -753K | 0 |
| Net income | -41.8M | -47.7M | -108.2M | -187.1M | -248.7M | -436.4M | -600.1M | -1.1B |
| EPS (diluted) | -21.24 | -22.33 | -2.01 | -2.57 | -3.08 | -3.86 | -3.58 | -5.95 |
| Diluted shares | - | - | 54.9M | 72.8M | 80.6M | 113.1M | 167.7M | 190.1M |
| Depreciation & amortization | 1.6M | 2.3M | 2.6M | 3.1M | 4.0M | 5.0M | 6.6M | 7.8M |
| EBITDA | -38.8M | -51.8M | -108.1M | -184.9M | -254.3M | -482.2M | -683.0M | -1.2B |
| Operating margin | -200.0% | -108.2% | -257.5% | -639.7% | -730.0% | -4207.1% | - | - |
| Net margin | -207.2% | -95.2% | -251.6% | -636.6% | -703.0% | -3768.3% | - | - |
| Revenue growth | - | +148% | -14.1% | -31.6% | +20.4% | -67.3% | -100% | - |
Balance sheet
From EDGAR| FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|---|---|---|---|
| Cash | 69.6M | 16.7M | 104.3M | 108.5M | 161.4M | 696.1M | 543.1M | 383.7M |
| Short-term investments | - | 106.1M | 336.5M | 468.6M | 483.5M | 1.2B | 1.7B | 1.6B |
| Receivables | - | - | - | - | - | - | - | 0 |
| Inventory | - | - | - | - | - | - | - | 0 |
| Current assets | - | 134.0M | 454.1M | 589.8M | 660.2M | 1.9B | 2.3B | 2.1B |
| Property & equipment | - | 7.1M | 8.9M | 11.5M | 18.7M | 22.9M | 24.3M | 33.2M |
| Goodwill | - | 14.6M | 14.6M | 14.6M | 14.6M | 14.6M | 14.6M | 14.6M |
| Other intangible assets | - | 62.0M | 60.9M | 59.9M | 58.8M | 57.7M | 56.7M | 55.8M |
| Total assets | - | 220.5M | 567.4M | 738.0M | 811.9M | 2.1B | 2.6B | 2.4B |
| Accounts payable | - | 11.4M | 12.6M | 14.1M | 21.3M | 61.8M | 54.4M | 64.6M |
| Current liabilities | - | 43.1M | 47.2M | 60.4M | 62.0M | 143.9M | 163.9M | 290.4M |
| Total liabilities | - | 68.0M | 92.7M | 135.4M | 126.7M | 235.5M | 293.1M | 723.2M |
| Shareholders' equity | -108.4M | -152.6M | 474.7M | 602.6M | 685.2M | 1.8B | 2.3B | 1.6B |
| Retained earnings | - | -157.4M | -265.5M | -452.6M | -701.3M | -1.1B | -1.7B | -2.9B |
Cash flow
From EDGAR| FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 1.2M | -49.6M | -100.1M | -147.2M | -224.4M | -350.6M | -557.4M | -897.7M |
| Capital spending | 1.5M | 2.6M | 2.9M | 6.5M | 10.8M | 7.7M | 10.3M | 16.0M |
| Free cash flow | -286K | -52.2M | -103.0M | -153.7M | -235.2M | -358.3M | -567.7M | -913.7M |
| Stock-based pay (added back) | 855K | 3.2M | 8.9M | 20.7M | 31.2M | 61.8M | 79.2M | 118.4M |
| Free cash flow after stock pay | -1.1M | -55.4M | -111.9M | -174.4M | -266.4M | -420.1M | -646.9M | -1.0B |
| Dividends paid | - | - | 0 | - | - | - | - | - |
| Investing cash flow | -1.3M | -102.0M | -234.2M | -142.1M | -24.1M | -342.6M | -554.4M | 118.1M |
| Financing cash flow | 60.8M | 98.7M | 422.8M | 294.2M | 301.4M | 1.2B | 959.4M | 621.5M |
Stock-based pay and leases
From EDGAR| FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|---|---|---|---|
| Stock-based pay (expense) | 855K | 3.2M | 8.9M | 20.7M | 31.2M | 61.8M | 79.2M | 118.4M |
| Stock-based pay / revenue | 4.2% | 6.3% | 20.7% | 70.5% | 88.2% | 533.4% | - | - |
| Operating lease cost | - | - | 2.7M | 5.5M | 8.9M | 8.5M | 12.2M | 18.8M |
| Operating lease cash paid | - | - | 2.6M | 1.5M | 2.4M | - | - | - |
| Right-of-use assets | - | - | 27.4M | 59.7M | 55.1M | 77.1M | 117.5M | 132.1M |
| Operating lease liabilities | - | - | 32.7M | 66.6M | 64.2M | 87.9M | 135.8M | 158.7M |
| Finance lease liabilities | - | - | 19K | - | - | - | - | - |
From SEC's XBRL company facts (data.sec.gov). EBITDA = operating income + depreciation and amortization; free cash flow = operating cash flow - capital spending; total debt = long-term debt (with its current part) + short-term borrowings. Stock-based pay and leases are shown as the company reports them; Tickdelta does not take them out of earnings or add leases to debt. Click a number to open the filing in SEC's Inline XBRL viewer, where you can click the same number to see how it is tagged. Values a company later revised show as revised; the Revised numbers tab lists the changes.
Sources
Every figure is from the company's XBRL filed with each 10-K and 10-Q (data.sec.gov). Hover a number for its line item; click it to open the filing.
Also
Company numbers: the figures the company reports beyond the statements. Peers: ten years, side by side.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/RVMD/export.csv") into a cell.